Minimal Residual Disease and Survival Outcomes in Patients with Mantle Cell Lymphoma: a systematic review and meta-analysis

Zhou, Yu; Chen, Haizhu; Tao, Yunxia; Zhong, Qiaofeng; Shi, Yuankai

doi:10.7150/jca.51959

International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

open access Global reach, higher impact

Full Text | PDF

J Cancer 2021; 12(2):553-561. doi:10.7150/jca.51959 This issue Cite

Research Paper

Minimal Residual Disease and Survival Outcomes in Patients with Mantle Cell Lymphoma: a systematic review and meta-analysis

Yu Zhou, Haizhu Chen, Yunxia Tao, Qiaofeng Zhong, Yuankai Shi^✉

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, 100021, China.

Citation:

Zhou Y, Chen H, Tao Y, Zhong Q, Shi Y. Minimal Residual Disease and Survival Outcomes in Patients with Mantle Cell Lymphoma: a systematic review and meta-analysis. J Cancer 2021; 12(2):553-561. doi:10.7150/jca.51959. https://www.jcancer.org/v12p0553.htm

Other styles

Abstract

Background: Minimal residual disease (MRD) has shown the prognostic value in mantle cell lymphoma (MCL). To quantify the relationships between progression free survival (PFS) and overall survival (OS) with MRD status in MCL, we conducted this meta-analysis.

Methods: We searched databases including Pubmed, Embase, Web of Science and the Cochrane Library up to July 15^th, 2020. Data of patients' characteristics, MRD assessment and survival outcomes were extracted and analyzed.

Results: Ten articles were included. For the impact of post-induction MRD status on survival outcomes, MRD positive status was associated with worse PFS (HR=1.44; 95%CI 1.27-1.62; P<0.00001) and OS (HR=1.30; 95%CI 1.03-1.64; P=0.03) compared with MRD negative status. Regarding the impact of post-consolidation MRD status on survival outcomes, MRD positivity predicted shorter PFS (HR=1.84; 95%CI 1.49-2.26; P<0.00001) and OS (HR=2.38; 95%CI 1.85-3.06; P<0.00001) than MRD negativity.

Conclusions: This study indicated that MRD positivity after induction and consolidation treatments was associated with worse PFS and OS for MCL. MRD-based treatment strategies should be further explored in clinical trials and real-world practice.

Keywords: minimal residual disease, mantle cell lymphoma, clinical outcome, prognosis, meta-analysis

Citation styles

APA

Zhou, Y., Chen, H., Tao, Y., Zhong, Q., Shi, Y. (2021). Minimal Residual Disease and Survival Outcomes in Patients with Mantle Cell Lymphoma: a systematic review and meta-analysis. Journal of Cancer, 12(2), 553-561. https://doi.org/10.7150/jca.51959.

ACS

Zhou, Y.; Chen, H.; Tao, Y.; Zhong, Q.; Shi, Y. Minimal Residual Disease and Survival Outcomes in Patients with Mantle Cell Lymphoma: a systematic review and meta-analysis. J. Cancer 2021, 12 (2), 553-561. DOI: 10.7150/jca.51959.

NLM

CSE

Zhou Y, Chen H, Tao Y, Zhong Q, Shi Y. 2021. Minimal Residual Disease and Survival Outcomes in Patients with Mantle Cell Lymphoma: a systematic review and meta-analysis. J Cancer. 12(2):553-561.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.